•
Sep 26, 2020

Thermo Fisher Q3 2020 Earnings Report

Thermo Fisher's Q3 2020 earnings significantly increased due to strong revenue growth and pandemic response.

Key Takeaways

Thermo Fisher Scientific reported a strong third quarter in 2020, with revenue increasing by 36% to $8.52 billion and adjusted EPS increasing by 91% to $5.63. The company benefited from $2.0 billion in COVID-19 related revenue and growth in its base business.

Revenue increased 36% to $8.52 billion.

GAAP diluted EPS increased 157% to $4.84.

Adjusted EPS increased 91% to $5.63.

Generated $2.0 billion of COVID-19 related revenue and returned the base business to growth.

Total Revenue
$8.52B
Previous year: $6.27B
+35.9%
EPS
$5.63
Previous year: $2.94
+91.5%
Adjusted Operating Margin
32.9%
Previous year: 22.7%
+44.9%
Gross Profit
$4.46B
Previous year: $2.89B
+54.3%
Cash and Equivalents
$7.54B
Previous year: $1.27B
+492.3%
Free Cash Flow
$2.34B
Previous year: $901M
+160.0%
Total Assets
$64.1B
Previous year: $56.7B
+12.9%

Thermo Fisher

Thermo Fisher

Thermo Fisher Revenue by Segment

Forward Guidance

Thermo Fisher is on track to deliver a record year and is positioning the company for an even brighter future.

Positive Outlook

  • Launching new products across the company.
  • Scaling up production of sample collection products.
  • Scaling up production of essential laboratory supplies.
  • Increasing pharma services capacity to support new therapies and vaccines.
  • Creating a strong foundation for future growth.

Revenue & Expenses

Visualization of income flow from segment revenue to net income